Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-12 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended period,Management of breakthrough pain in opioid-tolerant patients
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Fentanyl is primarily metabolized in the liver via CYP3A4-mediated N-dealkylation to norfentanyl, an inactive metabolite. Approximately 75% of the dose is excreted in urine, mainly as metabolites, with less than 10% as unchanged drug.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 80–85% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Approximately 6 L/kg (range 3–8 L/kg) after intravenous administration; high Vd indicates extensive tissue distribution and accumulation in fat and muscle.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Transdermal: approximately 92% relative to intravenous; absolute bioavailability is about 30–40% (due to first-pass metabolism, but transdermal bypasses hepatic first-pass, hence high relative bioavailability).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-89 m L/min: start at 50% of usual initial dose; GFR <30 m L/min: avoid use or start at 50% of usual dose with cautious titration. Not recommended in dialysis patients.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh class A: start at 50% of usual initial dose; Child-Pugh class B: start at 25% of usual dose; Child-Pugh class C: avoid use due to extreme risk of toxicity.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
For pediatric patients aged 2-16 years currently receiving and tolerant to opioids (equivalent to at least 60 mg oral morphine/day): initial fentanyl dose (mcg/h) based on previous 24-hour opioid requirement using standard conversion; apply patch every 72 hours. For opioid-naive pediatric patients: not recommended.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at 50% of usual adult starting dose (e.g., 12 mcg/h every 72 hours) due to increased sensitivity and reduced clearance; titrate cautiously with longer intervals between dose adjustments.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; ABUSE POTENTIAL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISK OF MEDICATION ERRORS; and RISK OF SERIOUS HARM OR DEATH WITH CONCOMITANT USE OF CYP3A4 INHIBITORS. DURAGESIC is contraindicated in the management of acute or intermittent pain, or in opioid-non-tolerant patients. Accidental exposure to DURAGESIC may result in fatal respiratory depression.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Life-threatening respiratory depression, especially during initiation or dose escalation,Accidental exposure can be fatal,Risk of abuse, misuse, and addiction,Risks from concomitant use with benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome with prolonged use during pregnancy,Risks of medication errors (e.g., confusion with other fentanyl products),Serotonin syndrome with concomitant serotonergic drugs,Adrenal insufficiency,Severe hypotension,Risks in patients with head injury or increased intracranial pressure,Application site reactions and skin irritation,Wound healing complications in patients with surgical wounds
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Opioid non-tolerant patients,Management of acute or intermittent pain,Postoperative pain management,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any components of the system
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid or limit grapefruit juice as it inhibits CYP3A4, increasing fentanyl levels and risk of adverse effects. No other significant food interactions. Alcohol should be avoided as it enhances central nervous system depression.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdrawal syndrome, respiratory depression, and decreased fetal growth; avoid prolonged use near term.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Fentanyl transfers into breast milk; M/P ratio approximately 0.17-0.47. Caution: risk of infant sedation and respiratory depression. Consider benefits vs risks; avoid if infant is <3 months or has respiratory compromise.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Pregnancy increases clearance of fentanyl by 35-50% in second and third trimesters; consider dose increase guided by pain response; postpartum clearance returns to prepregnancy levels within 48 h, requiring dose reduction.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
DURAGESIC-12 (fentanyl transdermal system) is indicated for opioid-tolerant patients only. Do not initiate in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on flat surface such as chest, back, flank, or upper arm. Avoid heat sources (heating pads, hot tubs, fever) which increase absorption. Monitor for constipation and respiratory depression, especially at start and dose titration. Not for acute pain or post-op use in opioid-naive patients.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Apply patch to clean, dry, non-hairy skin; do not cut or damage the patch.,Do not expose patch to direct heat (heating pads, hot tubs, electric blankets).,Keep patch away from children and pets; dispose of used patches by folding adhesive side together and flushing down toilet.,Do not drink grapefruit juice as it may increase fentanyl levels.,Do not stop using patch suddenly as withdrawal symptoms may occur.,Report severe drowsiness, confusion, difficulty breathing, or constipation.,Store at room temperature away from moisture and heat.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-12 vs ALFENTA, answered by our medical review team.
DURAGESIC-12 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-12 and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-12 is: Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-12 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-12 is classified as Category C. Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdra. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.